William Blair & Company’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History

William Blair & Company’s Portfolio PHAS Stock Details PHAS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-35,696	Closed	-$6K	–	1901
2022 Q3	$6K	Hold	35,696	–	–	﹤0.01%	1765
2022 Q2	$21K	Hold	35,696	–	–	﹤0.01%	1723
2022 Q1	$47K	Buy	35,696 +12,810	+56%	+$20.8K	﹤0.01%	1717
2021 Q4	$60K	Buy	22,886 +4,886	+27%	+$14.8K	﹤0.01%	1757
2021 Q3	$56K	Buy	18,000 +1,000	+6%	+$3.34K	﹤0.01%	1674
2021 Q2	$63K	Sell	17,000 -89,500	-84%	-$298K	﹤0.01%	1666
2021 Q1	$368K	Buy	106,500 +39,000	+58%	+$158K	﹤0.01%	1256
2020 Q4	$227K	Buy	+67,500	New	+$242K	﹤0.01%	1378

Other funds holding PHAS

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

HLA

Hamilton Lane Advisors Conshohocken, Pennsylvania $149M AUM 14.17% 1-Year Est. Return

IIA

IPG Investment Advisors San Diego, California $582M AUM 33.22% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

William Blair & Company's PHAS Position: Q4 2022 in Review

William Blair & Company sold out of PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) in Q4 2022, closing a stake of 35,696 shares — an estimated $6K sold.

William Blair & Company first reported a position in PHAS in Q4 2020 and held it in 8 quarters. The position peaked at $368K in Q1 2021. 5 funds tracked by Wall St. Rank hold PHAS as of Q4 2022.

William Blair & Company reported no remaining PhaseBio Pharmaceuticals, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
William Blair & Company sold 35,696 PhaseBio Pharmaceuticals, Inc. Common Stock shares in Q4 2022, an estimated $6K.
William Blair & Company first reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock in Q4 2020 and held it in 8 quarters.
William Blair & Company's PhaseBio Pharmaceuticals, Inc. Common Stock position peaked at $368K in Q1 2021.
5 funds tracked by Wall St. Rank held PhaseBio Pharmaceuticals, Inc. Common Stock as of Q4 2022.

Based on William Blair & Company's 13F filing for Q4 2022, filed 10 Feb 2023.